Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
-
- Max Hardy-Werbin
- Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Pedro Rocha
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
-
- Oriol Arpi
- Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Álvaro Taus
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
-
- Lara Nonell
- Microarrays analysis service, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Xavier Durán
- Statistics department, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Xavier Villanueva
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
-
- Deborah Joseph-Pietras
- NIHR Experimental Cancer Medicine Centre, Southampton, UK
-
- Luke Nolan
- Medical Oncology Department, University Hospital Southampton, Southampton, UK
-
- Sarah Danson
- Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, UK
-
- Richard Griffiths
- The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
-
- Miguel Lopez-Botet
- Immunology unit, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Ana Rovira
- Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Joan Albanell
- Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
-
- Christian Ottensmeier
- NIHR Experimental Cancer Medicine Centre, Southampton, UK
-
- Edurne Arriola
- Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain
収録刊行物
-
- OncoImmunology
-
OncoImmunology 8 (6), e1593810-, 2019-03-27
Informa UK Limited